Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice

Journal of Virology

Volumn 91, Issue 17, 2017, Pages

  Lennemann, Nicholas J ^a,c   Herbert, Andrew S ^b   Brouillette, Rachel ^a   Rhein, Bethany ^a,d   Bakken, Russell A ^b   Perschbacher, Katherine J ^a   Cooney, Ashley L ^a   Miller Hunt, Catherine L ^a,e   Eyck, Patrick Ten ^a   Biggins, Julia ^b   Olinger, Gene ^b,f   Dye, John M ^b   Maury, Wendy ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e WESTERN ILLINOIS UNIVERSITY   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ebola virus; Filovirus; Glycoproteins; Glycosylation; Pseudovirion; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON RECEPTOR; EBOLA VACCINE; GLYCAN; IMMUNOGLOBULIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONSERVED SEQUENCE; CONTROLLED STUDY; CROSS PROTECTION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LASSA VIRUS; MARBURGVIRUS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PSEUDOTYPING; RECEPTOR BINDING; SINGLE DRUG DOSE; VACCINATION; VESICULOVIRUS; VIRAL HEMORRHAGIC SEPTICEMIA; VIRION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

EID: 85027366684     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00479-17     Document Type: Article

References (76)

1. Incident Management System Ebola Epidemiology Team CDC, Guinea Interministerial Committee for Response Against the Ebola Virus, World Health Organization, CDC Guinea Response Team, Liberia Ministry of Health and Social Welfare, CDC Liberia Response Team, Sierra Leone Ministry of Health, CDC Sierra Leone Response Team, Viral Special Pathogens Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC. 2015. Update: Ebola virus disease epidemic-West Africa, January 2015. MMWR Morb Mortal Wkly Rep 64:109-110
2. Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG. 2012. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4:1619-1650. https://doi.org/10.3390/v4091619
3. Hoenen T, Groseth A, Feldmann H. 2012. Current ebola vaccines. Expert Opin Biol Ther 12:859-872. https://doi.org/10.1517/14712598.2012.685152
4. Sridhar S. 2015. Clinical development of Ebola vaccines. Ther Adv Vaccines 3:125-138. https://doi.org/10.1177/2051013615611017
5. Medaglini D, Harandi AM, OttenhoffTH, Siegrist CA, Consortium VS-E. 2015. Ebola vaccine R&D: filling the knowledge gaps. Sci Transl Med 7:317ps324. https://doi.org/10.1126/scitranslmed.aad3106
6. Ohimain EI. 2016. Recent advances in the development of vaccines for Ebola virus disease. Virus Res 211:174-185. https://doi.org/10.1016/j.virusres.2015.10.021
7. Mire CE, Geisbert TW, Feldmann H, Marzi A. 2016. Ebola virus vaccines-reality or fiction? Expert Rev Vaccines 15:1421-1430. https://doi.org/10.1080/14760584.2016.1178068
8. Henao-Restrepo AM, Preziosi MP, Wood D, Moorthy V, Kieny MP, WHO Ebola Research Development Team. 2016. On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa. Curr Opin Virol 17:138-144. https://doi.org/10.1016/j.coviro.2016.03.008
9. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 100:15889-15894. https://doi.org/10.1073/pnas.2237038100
10. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786-790. https://doi.org/10.1038/nm1258
11. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. 2010. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17:572-581. https://doi.org/10.1128/CVI.00467-09
12. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. 2002. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 76:9176-9185. https://doi.org/10.1128/JVI.76.18.9176-9185.2002
13. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153. https://doi.org/10.1016/S0264-410X(00)00113-4
14. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. 1998. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246:134-144. https://doi.org/10.1006/viro.1998.9176
15. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684. https://doi.org/10.1038/nature01876
16. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609. https://doi.org/10.1038/35046108
17. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81:6379-6388. https://doi.org/10.1128/JVI.00105-07
18. Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA. 2011. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 5:e1275. https://doi.org/10.1371/journal.pntd.0001275
19. Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF. 2015. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-Ebola vaccine. Virus Res 197:54-58. https://doi.org/10.1016/j.virusres.2014.11.028
20. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Konde MK, Keita S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Rottingen JA, Kieny MP. 23 December 2016. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet https://doi.org/10.1016/S0140-6736(16)32621-6
21. Cobleigh MA, Bradfield C, Liu Y, Mehta A, Robek MD. 2012. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol 86: 4253-4261. https://doi.org/10.1128/JVI.05991-11
22. Jeffers SA, Sanders DA, Sanchez A. 2002. Covalent modifications of the ebola virus glycoprotein. J Virol 76:12463-12472. https://doi.org/10.1128/JVI.76.24.12463-12472.2002
23. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182. https://doi.org/10.1038/nature07082
24. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. 2014. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. mBio 5:e00862-13
25. Lennemann NJ, Walkner M, Berkebile AR, Patel N, Maury W. 2015. The role of conserved N-linked glycans on Ebola virus glycoprotein 2. J Infect Dis 212(Suppl 2):S204-S209. https://doi.org/10.1093/infdis/jiv201
26. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. https://doi.org/10.1038/nature01470
27. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, Negrete OA, Bertolotti-Ciarlet A, Choi DY, McHardy I, Fulcher JA, Su SV, Wolf MC, Kohatsu L, Baum LG, Lee B. 2006. N-Glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80:4878-4889. https://doi.org/10.1128/JVI.80.10.4878-4889.2006
28. Biering SB, Huang A, Vu AT, Robinson LR, Bradel-Tretheway B, Choi E, Lee B, Aguilar HC. 2012. N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J Virol 86:11991-12002. https://doi.org/10.1128/JVI.01304-12
29. Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, Chen SW, Chen CM, Khoo KH, Cheng TJ, Cheng YS, Jan JT, Wu CY, Ma C, Wong CH. 2009. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A 106:18137-18142. https://doi.org/10.1073/pnas.0909696106
30. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J. 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84:11905-11915. https://doi.org/10.1128/JVI.01548-10
31. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109:9499-9504. https://doi.org/10.1073/pnas.1202924109
32. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF. 2011. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis 204(Suppl 3):S825-S832. https://doi.org/10.1093/infdis/jir295
33. Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C. 2007. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 81:1821-1837. https://doi.org/10.1128/JVI.02098-06
34. Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, Wood SC, Bavari S, Kaplan GG. 2011. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 29:2968-2977. https://doi.org/10.1016/j.vaccine.2011.01.113
35. Aviles J, Bello A, Wong G, Fausther-Bovendo H, Qiu X, Kobinger G. 2015. Optimization of prime-boost vaccination strategies against mouseadapted ebolavirus in a short-term protection study. J Infect Dis 212(Suppl 2):S389-S397. https://doi.org/10.1093/infdis/jiv175
36. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111:17182-17187. https://doi.org/10.1073/pnas.1414164111
37. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7:393-400. https://doi.org/10.1038/nrmicro2129
38. Sun Y, Carrion R, Jr, Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C. 2009. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383:12-21. https://doi.org/10.1016/j.virol.2008.09.020
39. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H. 2011. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204(Suppl 3): S1066-S1074. https://doi.org/10.1093/infdis/jir348
40. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. 2011. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A 108:20695-20700. https://doi.org/10.1073/pnas.1117715108
41. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109:5034-5039. https://doi.org/10.1073/pnas.1200409109
42. Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ. 2015. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One 10:e0118881. https://doi.org/10.1371/journal.pone.0118881
43. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. 2009. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 83:7296-7304. https://doi.org/10.1128/JVI.00561-09
44. Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM. 2013. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87:4952-4964. https://doi.org/10.1128/JVI.03361-12
45. Chen G, Koellhoffer JF, Zak SE, Frei JC, Liu N, Long H, Ye W, Nagar K, Pan G, Chandran K, Dye JM, Sidhu SS, Lai JR. 2014. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol 9:2263-2273. https://doi.org/10.1021/cb5006454
46. Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM. 2015. Interferon alpha/beta receptor-deficient mice as a model for Ebola virus disease. J Infect Dis 212(Suppl 2):S282-S294. https://doi.org/10.1093/infdis/jiv215
47. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. 2007. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3:e9. https://doi.org/10.1371/journal.ppat.0030009
48. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. 2002. Preand postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76:6408-6412. https://doi.org/10.1128/JVI.76.12.6408-6412.2002
49. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, LeDuc JW, Peters CJ. 1999. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179(Suppl 1):S224-S234. https://doi.org/10.1086/514310
50. Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C. 2006. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351:260-270. https://doi.org/10.1016/j.virol.2006.03.021
51. Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, Schmaljohn A, Bavari S, Aman MJ. 2004. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 40:27-31. https://doi.org/10.1016/S0928-8244(03)00273-6
52. Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S. 2007. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 196(Suppl 2):S421-S429. https://doi.org/10.1086/520612
53. Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. 2014. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101:26-29. https://doi.org/10.1016/j.antiviral.2013.10.012
54. Whitt MA, Geisbert TW, Mire CE. 2016. Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against highcontainment viruses. Methods Mol Biol 1403:295-311. https://doi.org/10.1007/978-1-4939-3387-7_16
55. Tober R, Banki Z, Egerer L, Muik A, Behmuller S, Kreppel F, Greczmiel U, Oxenius A, von Laer D, Kimpel J. 2014. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol 88:4897-4907. https://doi.org/10.1128/JVI.03276-13
56. Wu F, Fan X, Yue Y, Xiong S, Dong C. 2014. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine 32:3917-3926. https://doi.org/10.1016/j.vaccine.2014.05.052
57. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H. 2007. Assessment of a vesicular stomatitis virusbased vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 196(Suppl 2):S404-S412. https://doi.org/10.1086/520591
58. Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X. 2014. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32:5722-5729. https://doi.org/10.1016/j.vaccine.2014.08.028
59. Publicover J, Ramsburg E, Rose JK. 2005. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 79:13231-13238. https://doi.org/10.1128/JVI.79.21.13231-13238.2005
60. Zhang M, Dong C, Xiong S. 2017. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection. Hum Vaccin Immunother 13:816-822. https://doi.org/10.1080/21645515.2016.1261229
61. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM. 2009. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4:e5547. https://doi.org/10.1371/journal.pone.0005547
62. Schmaljohn A, Lewis GK. 2016. Cell-targeting antibodies in immunity to Ebola. Pathog Dis 74:ftw021. https://doi.org/10.1093/femspd/ftw021
63. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Jr, Saphire EO. 2015. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160:904-912. https://doi.org/10.1016/j.cell.2015.01.041
64. Beniac DR, Booth TF. 2017. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 A resolution. Sci Rep 7:46374. https://doi.org/10.1038/srep46374
65. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 6:e1000904. https://doi.org/10.1371/journal.ppat.1000904
66. Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. 2013. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis 7:e2600. https://doi.org/10.1371/journal.pntd.0002600
67. Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH. 2015. A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs. J Infect Dis 212(Suppl 2):S384-S388. https://doi.org/10.1093/infdis/jiv126
68. Lee JE, Fusco ML, Abelson DM, Hessell AJ, Burton DR, Saphire EO. 2009. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Acta Crystallogr D Biol Crystallogr 65:1162-1180. https://doi.org/10.1107/S0907444909032314
69. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4:363-371. https://doi.org/10.1038/nprot.2009.2
70. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB, Jr, Chiorini J, Maury W. 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A 108:8426-8431. https://doi.org/10.1073/pnas.1019030108
71. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. 1997. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 94:14764-14769. https://doi.org/10.1073/pnas.94.26.14764
72. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. 2015. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J Virol 90:266-278. https://doi.org/10.1128/JVI.02171-15
73. Lyles DS, Puddington L, McCreedy BJ, Jr. 1988. Vesicular stomatitis virus M protein in the nuclei of infected cells. J Virol 62:4387-4392
74. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC
75. Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, McCray PB, Jr, Quinn K, Weller ML, Chiorini JA, Maury W. 2011. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology 415:83-94. https://doi.org/10.1016/j.virol.2011.04.002
76. Hunt CL, Kolokoltsov AA, Davey RA, Maury W. 2011. The tyro3 receptor kinase axl enhances macropinocytosis of Zaire ebolavirus. J Virol 85: 334-347. https://doi.org/10.1128/JVI.01278-09